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Platelets assume the driving seat when it comes to arterial thrombosis. Subsequent to plaque rupture, they adhere to exposed subendothelial agonists, such as collagen and von Willebrand factor (vWF), in order to produce an initial platelet plug. The subendothelial ligands activate platelets, which change in shape and secrete thromboxane A 2 (TXA 2 ) and ADP. TXA 2 activates platelets further and ADP amplifies and sustains activation through platelet P2Y 12 receptors, leading to further expansion of the platelet-rich thrombus (Take home figure) . 1 Thrombin is also generated at the site of arterial injury, with activated platelets as well as tissue factor playing dominant roles in this, but pre-clinical data suggest that thrombin may play a greater role in stabilization of the core of the arterial thrombus rather than its expansion. 2 As a result, preventative therapy following acute coronary syndrome (ACS) consists of dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 inhibitor. 3, 4 Left ventricular thrombosis (LVT) can complicate ACS, particularly in those presenting late with ST-elevation myocardial infarction (STEMI). Blood stasis, inflamed myocardium, and hypercoagulable blood (representing the components of Virchow's triad) form the recipe for LVT, in which the protein arm of coagulation leading to fibrin clot formation is believed to play the primary role (Take home figure).
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Consequently, anticoagulation is recommended in these scenarios. 4 Although the incidence of LVT following ACS is declining in the era of primary angioplasty, treatment remains a challenge. On the one hand, antiplatelet therapy is needed to mitigate atherothrombotic risk; on the other hand, anticoagulant therapy is recommended to reduce the chances of systemic embolization (SE). However, triple therapy is associated with high risk of bleeding, and data on optimal antithrombotic approaches in this particular setting are lacking. 6 Moreover, the duration of anticoagulant therapy is the subject of ongoing debate. 6 In their analysis in this issue of the journal, Maniwa and colleagues aimed to assess the efficacy and risk associated with combined antiplatelet and anticoagulant therapy in a retrospective study of patients presenting with acute myocardial infarction (AMI) complicated by LVT. 7 In their single-centre study, all patients admitted with AMI over a 14-year period (2001-2014) were identified. A total of 1850 patients were included after excluding patients with previous ACS or coronary artery embolism, and those who did not survive their index admission. LVT occurred in 92 patients (5%). All patients were on an antiplatelet agent; 79% received oral anticoagulation primarily with vitamin K antagonists (VKAs), with target international normalized ratio (INR) 1.6-2.6, and 38% were on triple therapy. Anticoagulation was continued for a median of 34 months, and 41% discontinued anticoagulation mainly after LV thrombi dissolved. During a median follow-up of 5.4 years, 16.3% of patients with LVT had SE, compared with 2.9% in the absence of LVT (P < 0.001). Multivariable analysis confirmed LVT as an independent predictor of SE with a hazard ratio of 4 [95% confidecne interval (CI) 2.11-7.23]. Fourteen of the 15 patients with SE were either off anticoagulation or had subtherapeutic INRs. Events continued to occur beyond 2-3 years following ACS, and the majority of SEs were cerebrovascular. Two of the seven patients who had major bleeding events were on triple therapy and the rest were on warfarin and aspirin. Four of those events were intracranial haemorrhages. Patients with time in therapeutic range (TTR) of INR >50% and those with TTR <50% had similar bleeding event rates. In a field where data are very sparse, this study highlights the risks associated with LVT and the heterogeneity of current treatment strategies. The risk of SE seems to be high and remains so for a few years after AMI. Optimal levels of anticoagulation with warfarin offered reasonable protection against SE. On the other hand, all patients who had SE were receiving some form of antiplatelet therapy. This might imply lack of efficacy of antiplatelet therapy, although clopidogrel was primarily used and the variability in individual response to clopidogrel makes its efficacy and safety unpredictable. This study should stimulate further research in this area as several questions remain unanswered. One important question is how long to continue anticoagulant therapy. It can be argued from the presented data that long-term anticoagulation is necessary, but there are some caveats to this approach. LVT occurs as a response to myocardial and endocardial injury and, over time, the myocardial inflammation is expected to settle and lead to dissolution, organization, and endothelialization of thrombi, thus reducing the chances of SE. It could also be argued that late events occurring during this study might be related to other conditions such as either overt or undetected atrial fibrillation (AF), which is more common and associated with higher risk in those with heart failure, or atherothrombotic disease, which may be more severe and diffuse in those who have had a transmural STEMI as a result of more extensive coronary artery disease or late presentation. The small number of patients makes it difficult to ascertain the aetiology of these events. Undoubtedly, however, these patients require long-term follow-up with careful considerations of thrombotic and bleeding risks in order to individualize therapy.
The choice of anticoagulant therapy and optimal combination regimens is another area that has not been addressed by this study. Known limitations with VKAs have resulted in increased adoption of the non-VKA oral anticoagulants (NOACs). The efficacy of NOACs has been established in AF patients when compared with warfarin, with a favourable profile in terms of associated bleeding risk. [9] [10] [11] [12] Since there are similarities between the pathophysiology of LVT and AF-related cardiac thrombosis, it can be inferred that these anticoagulants are likely to be sufficient as a treatment option for patients with LVT. NOACs inhibit thrombin either directly (dabigatran) or indirectly by inhibiting factor Xa (rivaroxaban, apixaban, and edoxaban), with similar efficacy of either approach (Take home figure) .
The PIONEER-AF trial included patients with AF within 3 days of having percutaneous coronary intervention (PCI) and compared two rivaroxaban-based regimens (reduced dose rivaroxaban 15 mg daily In arterial thrombosis, platelets adhere to exposed subendothelial components, such as von Willebrand factor (vWF) and collagen, which induce release of thromboxane A 2 (TXA 2 ) and ADP, and, consequently, further platelet activation and expansion of the thrombus. Thrombin (IIa) is also generated at the site of arterial injury, primarily stabilizing the core platelet plug. Tissue factor (TF) expressed at the site of endocardial infarction leads to generation of thrombin and formation of ventricular thrombus. 'a' refers to activated clotting factors in the coagulation cascade. þ a P2Y 12 inhibitor or ultra-low dose rivaroxaban 2.5 mg twice daily þ DAPT) with triple therapy with warfarin þ DAPT. Triple therapy with warfarin resulted in greatly increased risk of clinically significant bleeding compared with each of the rivaroxaban-based regimens. Although this trial was not powered for efficacy, ischaemic outcomes were numerically similar across the three groups. 13 The REDUAL-PCI trial also included AF patients within 5 days of having PCI. A total of 2725 patients were randomized to one of three groups: triple therapy (warfarin þ DAPT), dual therapy (dabigatran 150 mg þ clopidogrel or ticagrelor), or dual therapy (dabigatran 110 mg þ clopidogrel or ticagrelor).
14 Aspirin was stopped in the triple therapy arm at 1 month if they had a bare metal stent or 3 months if they had a drug-eluting stent. Major bleeding was significantly reduced with dabigatran-based dual therapy. Similar to the PIONEER-AF trial, no significant differences in efficacy endpoints were present between the three treatment groups. The results of these two trials were similar to those of the WOEST trial, which compared warfarin-based triple therapy with dual therapy with warfarin and clopidogrel in 573 AF patients undergoing PCI. 15 Although these trials suggest that dual therapy (anticoagulant þ a P2Y 12 inhibitor) is sufficient in patients undergoing PCI and requiring anticoagulant therapy, patients with AMI are at high risk for recurrence of atherothrombotic disease, particularly in the acute period. As such, current guidelines reflect this and suggest triple therapy for 6 months following primary angioplasty except for those with very high risk of bleeding where an antiplatelet agent could be dropped at 1 month, or earlier in the case of aspirin. Moreover, most patients in the aforementioned trials were receiving clopidogrel. Combining potent P2Y 12 inhibitors (ticagrelor or prasugrel) and full anticoagulation is likely to result in a greater compromise to the haemostatic system and possibly an unacceptably high risk of bleeding, most certainly when also including aspirin in the combination. As such, guidelines warn against such a combination.
In summary, the results reported in this study highlight the risks associated with LVT following AMI. Anticoagulation can be effective at mitigating the risk of SE, but long-term follow-up is likely to be needed to consider carefully the duration and intensity of therapy. Trials are needed to explore the optimum antithrombotic therapy in this patient cohort and may be informed by recent and ongoing studies of combination therapy in AF patients with an indication for DAPT.
